Invalid Symbol

Stock Research for MSLI

MSLI
Current Price

$


Latest Update:

High
$
Low
$
Close
$
Volume
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

MSLI Stock Chart & Research Data

The MSLI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MSLI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


MSLI Due diligence Resources & Stock Charts

The MSLI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MSLI Detailed Price Forecast - CNN Money CNN View MSLI Detailed Summary - Google Finance
Yahoo View MSLI Detailed Summary - Yahoo! Finance Zacks View MSLI Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View MSLI Trends & Analysis - Trade-Ideas Barrons View MSLI Major Holders - Barrons
NASDAQ View MSLI Call Transcripts - NASDAQ Seeking View MSLI Breaking News & Analysis - Seeking Alpha
Spotlight View MSLI Annual Report - CompanySpotlight.com OTC Report View MSLI OTC Short Report - OTCShortReport.com
TradeKing View MSLI Fundamentals - TradeKing Charts View MSLI SEC Filings - Bar Chart
WSJ View Historical Prices for MSLI - The WSJ Morningstar View Performance/Total Return for MSLI - Morningstar
MarketWatch View the Analyst Estimates for MSLI - MarketWatch CNBC View the Earnings History for MSLI - CNBC
StockMarketWatch View the MSLI Earnings - StockMarketWatch MacroAxis View MSLI Buy or Sell Recommendations - MacroAxis
Bullish View the MSLI Bullish Patterns - American Bulls Short Pains View MSLI Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View MSLI Stock Mentions - StockTwits PennyStocks View MSLI Stock Mentions - PennyStockTweets
Twitter View MSLI Stock Mentions - Twitter Invest Hub View MSLI Investment Forum News - Investor Hub
Yahoo View MSLI Stock Mentions - Yahoo! Message Board Seeking Alpha View MSLI Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for MSLI - SECform4.com Insider Cow View Insider Transactions for MSLI - Insider Cow
CNBC View MSLI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MSLI - OTC Markets
Yahoo View Insider Transactions for MSLI - Yahoo! Finance NASDAQ View Institutional Holdings for MSLI - NASDAQ


Stock Charts

FinViz View MSLI Stock Insight & Charts - FinViz.com StockCharts View MSLI Investment Charts - StockCharts.com
BarChart View MSLI Stock Overview & Charts - BarChart Trading View View MSLI User Generated Charts - Trading View


Latest Financial News for MSLI

Norgine B.V. completes acquisition of Merus Labs International Inc. strengthening its leading position in the European specialist pharma market
Posted on Monday July 17, 2017

TORONTO and AMSTERDAM, The Netherlands, July 17, 2017 /PRNewswire/ - Norgine B.V. ("Norgine") and Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI) ("Merus" or the "Company") are pleased to announce the closing of the plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement"). Norgine and Merus previously announced the signing of the arrangement agreement in respect of the Arrangement in a press release issued on May 11, 2017 and the issuance of the final order of the Supreme Court of British Columbia in respect of the Arrangement in a press release issued on July 12, 2017.


Featured Company News - A Majority of Merus Labs' Shareholders Approve Acquisition by Dutch Pharma Major Norgine B.V.
Posted on Thursday July 13, 2017

LONDON, UK / ACCESSWIRE / July 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Merus Labs International Inc. (NASDAQ: MSLI ), following which we ...


Merus Labs International Inc. Receives Court Approval in Connection with Proposed Plan of Arrangement with Norgine B.V.
Posted on Wednesday July 12, 2017

TORONTO, July 12, 2017 /PRNewswire/ - Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI) ("Merus" or the "Company") announced today that the Supreme Court of British Columbia has issued a final order approving the proposed transaction pursuant to which Norgine B.V. agreed to acquire all of the issued and outstanding common shares of Merus by way of a plan of arrangement (the "Arrangement"). Merus is a specialty pharmaceutical company focused on acquiring and optimizing legacy and growth products. Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets.


Merus Labs International Inc. Shareholders Approve Plan of Arrangement with Norgine B.V.
Posted on Monday July 10, 2017

TORONTO and AMSTERDAM, July 10, 2017 /PRNewswire/ - Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI) ("Merus" or the "Company") announced that at a special meeting of shareholders held earlier today (the "Meeting"), Merus shareholders voted in favour of the proposed transaction pursuant to which Norgine B.V. ("Norgine") agreed to acquire all of the issued and outstanding common shares of Merus by way of a plan of arrangement (the "Arrangement"). The Arrangement was approved by approximately 99.79% of the votes cast by all of the Merus shareholders eligible to vote at the Meeting.


Norgine in $342 million deal to buy Merus
The Pharma Letter - May 11, 2017
Independent drugmaker Norgine is to acquire specialty pharma company Merus Labs International (Nasdaq: MSLI) in a $342 million deal, news of which sent the latter company's share price spiraling by 54% to $1.19 in Thursday morning's trading. Norgine, a ...

Pharmaceutical M&A deals in 2017
The Pharma Letter - Jan 3, 2018
In 2017, deal volume in the healthcare sector overall was very active as far as mergers and acquisitions (M&A) were concerned.

Top 10 European Biopharma Clusters
Genetic Engineering & Biotechnology News - Jun 19, 2017
A provocative study published earlier this month in the journal Science and Public Policy contends that Europe lacks the cutting-edge science long seen in the U.S.

PDL BioPharma Announces Fourth Quarter and Year End 2016 Financial Results
PR Newswire (press release) - Mar 1, 2017
In 2012, the Company began providing alternative sources of capital through royalty monetizations and debt facilities, and in 2016, the Company began acquiring commercial-stage products and launching specialized companies dedicated to the ...

Enter a stock symbol to view the stock details.